Novo Nordisk posts PIONEER TEENS results; registers three new trials for obesity and injections

Novo Nordisk's most notable update this week was the results posting for its pediatric type 2 diabetes trial, alongside three newly registered studies.

• PIONEER TEENS, a Phase 3 trial of oral semaglutide versus placebo in children and adolescents with type 2 diabetes, is now listed as completed with results first posted on 2026-08-21. The study enrolled 132 participants and compared oral semaglutide against placebo in combination with metformin and/or basal insulin¹, with primary completion recorded as 2025-04-29.
• OASIS 5, a Phase 3 trial testing oral semaglutide for weight loss in adults with overweight or obesity, opened for recruitment on 2026-08-12. The study will evaluate how oral semaglutide, taken in lower doses, helps lower body weight in participants with excess body weight when compared to placebo tablets², with an estimated enrollment of 450 participants.
• A first-in-human Phase 1 trial of NNC0721-8060 in adults with overweight or obesity began recruiting on 2026-08-12. The study compares NNC0721-8060 against an active semaglutide comparator and placebo³, with estimated enrollment of 142 participants.
• The RISE study, a Phase 1 trial in healthy participants, opened for recruitment on 2026-08-17 to examine the tolerability of different injection and infusion volumes and speeds compared to standard practice⁴, with an estimated enrollment of 100 participants.